The global pharmaceutical isolator market size was estimated to be US$ 5.75 billion in 2021 and is expected to grow at a CAGR of 5.4% between 2023 to 2032.
In the pharmaceutical sector, to achieve an aseptic environment is imperative to protect the function or activity from any unwanted microbiological and non-viable contamination caused by the operator and the surrounding environment. For this purpose a device known as pharmaceutical isolator is used to isolate a pharmaceutical process or activity from the operator as well as the rest of the environment.
In the pharmaceutical sector, isolators are used as a contamination-free barrier system. Such systems are needed for cell therapy processing, microbiological testing, advanced therapy medicinal product (ATMP) manufacturing, and for packing and weighing purposes. As a consequence of the continued growth of the pharmaceutical market in both emerging and established countries, there is also a growing demand for the use of pharmaceutical isolators. By catering to pharma industry specific demands and by improving the technology of the isolators, the pharmaceutical isolator market will continue to grow.
There are multiple drivers of growth in the pharmaceutical isolator market primarily due to the rise in research and development laboratories, the increasing cost of non-compliance and the increasing use of hazardous compounds. As the interior of the pharmaceutical isolator is isolated from the outside environment, commonly used drugs, quality control activities and goods are isolated from outside world.
Currently, majority of pharmaceutical isolators manufactured are specially catered to the needs of research and manufacturing organizations. Lower operating costs and lower procuring cost than standard clean rooms are primary drivers of market growth. As pharmaceutical isolators guarantee sterility, advanced mobility and coherence in active pharmaceutical ingredient (API) manufacturing, drug safety regulatory approvals are easier to obtain for businesses.
The global pandemic of COVID-19 has given biopharmaceutical and pharmaceutical companies numerous opportunities to increase their research and development budgets in order to develop novel molecules, compounds and vaccines for containing the spread and treatment of seriously ill patients. As the number of clinical trials increase so does the need for biopharmaceutical organizations to procure and install pharmaceutical isolators.
Industry experts are not convinced that drug regulatory authorities are promoting/advocating the use of breakthroughs like pharmaceutical isolators. The demand for pharmaceutical isolators as containment solutions in food, cosmetics and detergent industries remains to be seen.
The major players operating in the pharmaceutical isolator market are listed below Skan AG, COMECER S.p.A, Robert Bosch GmbH, Klenzaids, Nuaire, M.A. SpA, Syntegon Technologies GmbH, Esco Micro Pte Ltd, Hosokawa Micron Ltd, Getinge AB, Azbil Telstar, Iso Tech Design, BRAUN INERTGAS-SYSTEME GMBH and others.
The global pharmaceutical isolator market is estimated to exhibit a CAGR of 5.4% by 2032.
The pharmaceutical isolator market was valued at US$ 5.75 billion in 2021.
Growth in the pharmaceutical isolator market primarily due to the rise in research and development laboratories, the increasing cost of non-compliance and the increasing use of hazardous compounds.
The end-use segments in pharmaceutical isolator market are Hospitals, Diagnostic laboratories, Academic and research institutes, Pharmaceutical and biotechnology companies and Contract research organization.
Major participants in the pharmaceutical isolator industry comprise Skan AG, COMECER S.p.A, Robert Bosch GmbH, Klenzaids, Nuaire, M.A. SpA, Syntegon Technologies GmbH, Esco Micro Pte Ltd, Hosokawa Micron Ltd, Getinge AB, Azbil Telstar, Iso Tech Design, BRAUN INERTGAS-SYSTEME GMBH and others.
Copyright © 2024 Same Page Management Consulting Pvt. Ltd. (insightSLICE) | All Rights Reserved